UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-06, Vol.382 (23), p.2197-2206

2020

Volltextzugriff (PDF)

Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective

Urology (Ridgewood, N.J.), 2015-04, Vol.85 (4), p.717-724

Shore, Neal D

2015

Volltextzugriff (PDF)

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

The lancet oncology, 2016-02, Vol.17 (2), p.153-163

2016

Volltextzugriff (PDF)

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

The Journal of urology, 2021-09, Vol.206 (3), p.715-724

2021

Volltextzugriff (PDF)

Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36

European urology open science (Online), 2022-12, Vol.46, p.145-146

Shore, Neal D.

2022

Volltextzugriff (PDF)

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

European urology, 2016-12, Vol.70 (6), p.963-970

2016

Volltextzugriff (PDF)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.1758835921998586

2021

Volltextzugriff (PDF)

Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer

Clinical genitourinary cancer, 2021-06, Vol.19 (3), p.199-207

2021

Volltextzugriff (PDF)

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

The Prostate, 2019-05, Vol.79 (6), p.604-613

2019

Volltextzugriff (PDF)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

BMJ open, 2021-08, Vol.11 (8), p.e046588-e046588

2021

Volltextzugriff (PDF)

Experience with degarelix in the treatment of prostate cancer

Therapeutic Advances in Urology, 2013-02, Vol.5 (1), p.11-24

Shore, Neal D.

2013

Volltextzugriff (PDF)

The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy

Urologic oncology, 2017-05, Vol.35 (5), p.183-191

2017

Volltextzugriff (PDF)

Mechanism of action of nadofaragene firadenovec-vncg

Frontiers in oncology, 2024, Vol.14, p.1359725-1359725

2024

Volltextzugriff (PDF)

Darolutamide (ODM-201) for the treatment of prostate cancer

Expert opinion on pharmacotherapy, 2017-06, Vol.18 (9), p.945-952

Shore, Neal D.

2017

Volltextzugriff (PDF)

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer

Cancers, 2023-10, Vol.15 (19), p.4854

2023

Volltextzugriff (PDF)

Complications of immuno‐oncology care: what urologist should know

BJU international, 2024-05, Vol.133 (5), p.524-531

2024

Volltextzugriff (PDF)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases

Targeted oncology, 2023-01, Vol.18 (1), p.95-103

2023

Volltextzugriff (PDF)

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

Archivio italiano di urologia, andrologia, 2024-03, Vol.96 (1), p.12244

2024

Volltextzugriff (PDF)

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of clinical oncology, 2019-11, Vol.37 (32), p.2974-2986

2019

Volltextzugriff (PDF)

Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

Journal of health economics and outcomes research (Online), 2021-05, Vol.8 (1), p.42-50

2021

Volltextzugriff (PDF)

Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey

Clinical genitourinary cancer, 2018-04, Vol.16 (2), p.e411-e419

2018

Volltextzugriff (PDF)

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials

European urology focus, 2018-07, Vol.4 (4), p.547-553

2018

Volltextzugriff (PDF)

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-07, Vol.402 (10398), p.291-303

2023

Volltextzugriff (PDF)

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

The New England journal of medicine, 2020-06, Vol.382 (23), p.2187-2196

2020

Volltextzugriff (PDF)

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

Urologic oncology, 2015-05, Vol.33 (5), p.245-260

2015

Volltextzugriff (PDF)

1 – 25 von 666

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(618)
Mit Volltextzugriff
(478)

Publikationsform

Sprache

Englisch
(666)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(226)
Life Sciences & Biomedicine
(224)
Humans
(173)
Male
(158)
Urology & Nephrology
(126)
Oncology
(112)
Prostate Cancer
(94)
Urology
(76)
Aged
(75)
Middle Aged
(63)
Metastasis
(50)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(45)
Treatment Outcome
(45)
Aged, 80 And Over
(42)
Prostatic Neoplasms - Drug Therapy
(38)
Patients
(36)
Prostatic Neoplasms, Castration-Resistant - Pathology
(35)
Metastases
(32)
Androgens
(31)
Prostatic Neoplasms - Pathology
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(274)
The Journal Of Urology
(79)
Reviews In Urology
(22)
The journal Of Urology/the journal Of Urology
(21)
European Urology
(20)
Urology
(19)
Urologic Oncology
(15)
Urology Times
(13)
Future Oncology
(11)
Clinical Cancer Research
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer

Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

Experience with degarelix in the treatment of prostate cancer

The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy

Mechanism of action of nadofaragene firadenovec-vncg

Darolutamide (ODM-201) for the treatment of prostate cancer

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer

Complications of immuno‐oncology care: what urologist should know

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

Suchergebnisse filtern